Literature DB >> 29932012

Choroideremia: molecular mechanisms and development of AAV gene therapy.

Maria I Patrício1,2,3, Alun R Barnard1,2,3, Kanmin Xue1,2,3, Robert E MacLaren1,2,3.   

Abstract

INTRODUCTION: Choroideremia is an X-linked inherited retinal degeneration that causes blindness in afflicted males by middle age. The causative gene, CHM, plays a key role in intracellular trafficking pathways, and its disruption impairs cell homeostasis. AREAS COVERED: The mechanism by which mutations in CHM cause choroideremia is still under debate. Here we describe the molecular defects in choroideremia cells regarding both the deficiency of prenylation and the involvement of Rab GTPases. Important in vivo and in vitro studies that contributed to the current knowledge are also discussed. Finally, the rationale for the development of a treatment strategy using AAV for gene replacement is presented, together with other treatment strategies under consideration. EXPERT OPINION: Despite ubiquitous expression of the CHM gene, the primary defect in choroideremia is driven by retinal pigment epithelium (RPE) and photoreceptors degeneration. Here we discuss how impairment of vesicular trafficking pathways in the RPE plays a major role in the molecular pathogenesis of choroideremia. Moreover, this defect is likely restored by subretinal delivery of a functional copy of CHM using AAV, as evidenced by clinical trial results. The surgical complexity of delivering the AAV vector to the target area remains as the main challenge to this therapy. ABBREVIATIONS: AAV: adeno-associated virus; BCD: Bietti's crystalline dystrophy; CHM: choroideremia; CHML: choroideremia-like; Dfp: days post-fertilization; EMA: European Medicines Agency; ERG: electroretinogram; ETDRS: Early Treatment Diabetic Retinopathy Study; FDA: Food and Drug Administration; FTase: farnesyl transferase; GFP: green fluorescent protein; GGPP: geranylgeranyl-diphosphate; GGTase-I: geranylgeranyl transferase type-I; GGTase-II: geranylgeranyl transferase type-II; HMG-CoA: 3-hydroxy-3-methylglutayl-CoA; HMGCR: HMG-CoA reductase; iPSC: induced pluripotent stem cells; IRDs: inherited retinal diseases; KO: knockout; LCA: Leber congenital amaurosis; NMD: nonsense-mediated mRNA decay; OCT: optical coherence tomography; PMBCs: peripheral blood mononuclear cells; POS: photoreceptor outer segments; PTCs: premature termination codons; Rab GGTase: Rab geranylgeranyl transferase; REP: Rab escort protein; RPE: retinal pigment epithelium; TRIDs: translational read-through inducing drugs; WPRE: woodchuck post-transcriptional regulatory element.

Entities:  

Keywords:  AAV; Rab GTPases; choroideremia; clinical trials; gene therapy; prenylation

Mesh:

Year:  2018        PMID: 29932012     DOI: 10.1080/14712598.2018.1484448

Source DB:  PubMed          Journal:  Expert Opin Biol Ther        ISSN: 1471-2598            Impact factor:   4.388


  14 in total

1.  AAV-Mediated Neurotrophin Gene Therapy Promotes Improved Survival of Cochlear Spiral Ganglion Neurons in Neonatally Deafened Cats: Comparison of AAV2-hBDNF and AAV5-hGDNF.

Authors:  Patricia A Leake; Stephen J Rebscher; Chantale Dore'; Omar Akil
Journal:  J Assoc Res Otolaryngol       Date:  2019-06-20

2.  The Role of FGF9 in the Production of Neural Retina and RPE in a Pluripotent Stem Cell Model of Early Human Retinal Development.

Authors:  David M Gamm; Eric Clark; Elizabeth E Capowski; Ruchira Singh
Journal:  Am J Ophthalmol       Date:  2019-05-10       Impact factor: 5.258

3.  Three-Year Safety Results of SAR422459 (EIAV-ABCA4) Gene Therapy in Patients With ABCA4-Associated Stargardt Disease: An Open-Label Dose-Escalation Phase I/IIa Clinical Trial, Cohorts 1-5.

Authors:  Maria A Parker; Laura R Erker; Isabelle Audo; Dongseok Choi; Saddek Mohand-Said; Kastytis Sestakauskas; Patrick Benoit; Terence Appelqvist; Melissa Krahmer; Caroline Ségaut-Prévost; Brandon J Lujan; Ambar Faridi; Elvira N Chegarnov; Peter N Steinkamp; Cristy Ku; Mariana Matioli da Palma; Pierre-Olivier Barale; Sarah Ayelo-Scheer; Andreas Lauer; Tim Stout; David J Wilson; Richard G Weleber; Mark E Pennesi; José Alain Sahel; Paul Yang
Journal:  Am J Ophthalmol       Date:  2022-03-04       Impact factor: 5.488

4.  Clade F AAVHSCs cross the blood brain barrier and transduce the central nervous system in addition to peripheral tissues following intravenous administration in nonhuman primates.

Authors:  Jeff L Ellsworth; Jacinthe Gingras; Laura J Smith; Hillard Rubin; Tania A Seabrook; Kruti Patel; Nicole Zapata; Kevin Olivieri; Michael O'Callaghan; Elizabeth Chlipala; Pablo Morales; Albert Seymour
Journal:  PLoS One       Date:  2019-11-26       Impact factor: 3.240

Review 5.  Update on Gene Therapy Clinical Trials for Choroideremia and Potential Experimental Therapies.

Authors:  Alessandro Abbouda; Filippo Avogaro; Mariya Moosajee; Enzo Maria Vingolo
Journal:  Medicina (Kaunas)       Date:  2021-01-12       Impact factor: 2.430

6.  Curative gene therapies for rare diseases.

Authors:  Rocio Maldonado; Sami Jalil; Kirmo Wartiovaara
Journal:  J Community Genet       Date:  2020-08-15

7.  Synonymous Variant in the CHM Gene Causes Aberrant Splicing in Choroideremia.

Authors:  Mariana Matioli da Palma; Fabiana Louise Motta; Caio Perez Gomes; Mariana Vallim Salles; João Bosco Pesquero; Juliana Maria Ferraz Sallum
Journal:  Invest Ophthalmol Vis Sci       Date:  2020-02-07       Impact factor: 4.799

8.  Quantification of RPE Changes in Choroideremia Using a Photoshop-Based Method.

Authors:  Yi Zhai; Manlong Xu; Ioannis S Dimopoulos; David G Birch; Paul S Bernstein; Jenny Holt; David Kirn; Peter Francis; Ian M MacDonald
Journal:  Transl Vis Sci Technol       Date:  2020-06-18       Impact factor: 3.283

Review 9.  Molecular Therapies for Choroideremia.

Authors:  Jasmina Cehajic Kapetanovic; Alun R Barnard; Robert E MacLaren
Journal:  Genes (Basel)       Date:  2019-09-23       Impact factor: 4.096

10.  Inclusion of PF68 Surfactant Improves Stability of rAAV Titer when Passed through a Surgical Device Used in Retinal Gene Therapy.

Authors:  Maria I Patrício; Christopher I Cox; Clare Blue; Alun R Barnard; Cristina Martinez-Fernandez de la Camara; Robert E MacLaren
Journal:  Mol Ther Methods Clin Dev       Date:  2019-11-20       Impact factor: 6.698

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.